← Quality Momentum
QM · rank #17 · 2026-10-26
ILMN
NASDAQ · $40.68B (USD)
SignalSell
verdict · CAUTION
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +194.47% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +32.3% |
| Profit margin Net profit margin, trailing 12 months. | +18.3% |
| Market cap (USD) Size filter: > $500M required. | $40.68B |
| Anchor (recent) Close on 2026-09-25 | $270.00 |
| Anchor (far) Close on 2025-09-26 | $91.69 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
ILMN is a leading DNA-sequencing and genomics tools company selling instruments, consumables, software, and emerging multiomics/clinical workflows worldwide.
Rationale
The signal is supported by strong quality and trend factors—12-1 momentum is strong, ROE and margins are healthy, and Q2 showed revenue growth, raised FY2026 guidance, and solid free cash flow.
Material risks
- 1China export restrictions and the Unreliable Entities List can directly block instrument sales and pressure a meaningful international revenue channel.
- 2Intense sequencing competition could still erode pricing and volumes if rivals force commoditization or customers internalize more analysis capability.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Caution